Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial

Xiaohua Wu(Fudan University Shanghai Cancer Center), Mansoor Raza Mirza(C4 Therapeutics (United States)), Juan Dong(Zhejiang A & F University), Yi Huang(Hubei Cancer Hospital), Xin Lü(Obstetrics and Gynecology Hospital of Fudan University), Min Hao(Shanxi Medical University), Xiaofei Tian(Chinese Academy of Sciences), Beihua Kong(Qilu Hospital of Shandong University), Charlie Zhang, Lipai Chen(Jilin Province Tumor Hospital), Lingying Wu(Chang Gung University), Xianghua Huang(Nanjing General Hospital of Nanjing Military Command), Jianmei Hou, Ke Wang(Tianjin Medical University Cancer Institute and Hospital), Xiaojian Yan(Wenzhou Medical University), Qionghua Chen(First Affiliated Hospital of Xiamen University), Yunong Gao, Ruifang An(First Affiliated Hospital of Xi'an Jiaotong University), Rutie Yin(Sichuan University), Zhao Huang, Li Wang(State Key Laboratory of Chemical Engineering), Jing Wang(NYU Langone Health), Jihong Liu(Sun Yat-sen University), Yu Zhang(Wannan Medical College), Weiguo Lu(Women's Hospital, School of Medicine, Zhejiang University), Guiling Li(Union Hospital), Ge Lou(Harbin Medical University), Hongying Yang(Kunming Medical University), Heng Cui(Peking University), Hao Wen(Second Affiliated Hospital of Nanjing Medical University), Qi Zhou(Fudan University), Jiaxin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ziling Liu(Jilin University), Danbo Wang(Qinghai University), Guzhalinuer Abulizi(Xinjiang Medical University), Jianqing Zhu
EClinicalMedicine
May 7, 2024
Cited by 24


Related Papers